Top 100 Clinical Project Manager Hiring Companies & CROs (2025 Complete Directory)
Clinical Project Managers win 2025 by blending inspection-ready GCP discipline, risk-based planning, and budget control that keeps trials on schedule. If you’re aiming for interviews this quarter, anchor your habits in GCP guidelines mastery, keep artifacts ALCOA+ clean via clinical trial documentation under GCP, turn uncertainty into CAPA using protocol deviation strategies, and speak like a CFO with budget oversight best practices. Use project planning techniques to run weekly cadence, and for country nuance, cite 2025 trial hotspots so your timelines sound grounded.
What hiring managers want from CPMs in 2025 (so your résumé sounds inspection-ready)
The fastest callbacks go to CPMs who prove they can stabilize risk early and translate endpoints into executable plans. Showcase RAID logs driven by risk-management logic, budget re-forecasts aligned to oversight KPIs, and GCP-clean documentation per ALCOA+. If you’re moving from CRC/CRA, translate site wins into portfolio-level delivery using PI leadership cues and protocol development fluency; recruiters love to see inspection-calm language paired with proven test-taking clarity in interviews.
Your application stack (3 artifacts that book interviews fast)
Send a one-page plan that mirrors project planning essentials; attach a budget control snapshot tied to oversight metrics; and include a GCP documentation sample showing ALCOA+ rigor plus a short CAPA trail grounded in deviation management. Signal geographic fluency with country trend insights and runway awareness (e.g., UK’s environment via Brexit impacts).
| Company / CRO | Trial Focus & What CPMs Drive | Hiring Notes (US / Remote / Hybrid) |
|---|---|---|
| IQVIA | Full-service CRORBQM Portfolio CPM roles across oncology/CVRM; heavy vendor orchestration. | US nationwide; hybrid with travel. |
| ICON | OncologyCell/Gene Late-phase scale; CPI oversight & change control. | Hybrid hubs; remote teams growing. |
| Labcorp Drug Development | Early→lateBiostats CPMs integrate labs, timelines, inspection prep. | US remote with hub visits. |
| Parexel | Phase II–IIIReg Strat Risk-based plans; CAPA governance. | Remote/hybrid, coast-to-coast. |
| PPD (Thermo Fisher) | MultitherapyStart-up CPMs drive site activation SLAs. | US hubs + remote options. |
| Syneos Health | BiotechLaunch Integrated med/commercial timelines. | Hybrid; travel per study. |
| Medpace | OncRare High discipline TMF & issue management. | Hybrid; select remote CPM. |
| Precision for Medicine | BiomarkerOnc Assay/logistics complexity; CPMs own risk logs. | Remote/hybrid. |
| PSI CRO | GlobalOnc Country nuance; forecast discipline. | Remote with travel. |
| Worldwide Clinical Trials | NeuroRare Mid-size agility + inspection calm. | US remote/hybrid. |
| Clinipace / Caidya | OncAsia-US Cross-region timelines; vendor harmonization. | Remote/hybrid. |
| Veristat | RareBiostats IND→NDA arcs; CPMs own decision gates. | US remote. |
| Premier Research | DeviceOrphan Hybrid PMO; design controls literacy. | Hybrid; selective remote. |
| TFS HealthScience | OncDerm Country activation risk maps. | Remote/hybrid. |
| KCR | EMEA/USOnc CPMs drive RBQM dashboards. | US remote. |
| Phastar | BiostatsData CPMs align data timelines to readouts. | Remote/hybrid. |
| Inotiv | Preclinical→Clinical Cross-phase integration; supplier control. | Hybrid. |
| WCG | IRBServices Start-up accelerators; CPM interface. | US remote/hybrid. |
| Allucent | Small Biotech Scrappy timelines; CPMs own comms. | Remote. |
| Charlottesville CRO (Fict. Example) | Academic tie-ins Teaching hospital networks; CPM site cadence. | Hybrid regional. |
| Pfizer | OncVaccines CPMs orchestrate country start-up, budget control. | Hubs + remote. |
| Novartis | OncCardio Complex vendor stacks; strong PMO culture. | Hybrid; travel. |
| Roche/Genentech | OncOphth Biomarker ops; inspection-ready TMF. | Hybrid. |
| Merck & Co. (MSD) | IOVaccines Global CPM; site performance governance. | Hybrid/remote. |
| Johnson & Johnson (Janssen) | ImmunologyNeuro CAPA rigor; budget re-forecasts. | Hybrid. |
| Bristol Myers Squibb | OncCardio Readiness rooms; escalation discipline. | US hubs + remote. |
| GSK | RespVaccines Country activation playbooks. | Hybrid. |
| AstraZeneca | OncCVRM Cross-asset CPM orchestration. | Hybrid/remote. |
| Sanofi | RareImmunology COE site nuance; global affiliates. | Hybrid. |
| Amgen | OncBone Portfolio sequencing; KPI boards. | Hybrid. |
| Eli Lilly | ObesityOnc Scale & pace; CPMs own risk burndown. | Hybrid. |
| Novo Nordisk | DiabetesObesity Real-world rollout tempo. | Hybrid. |
| Bayer | CardioOnc Signal-to-plan conversion. | Hybrid. |
| Boehringer Ingelheim | RespCardio-renal Multispecialty site grids. | Hybrid. |
| AbbVie | ImmunologyNeuro Long-arc trials; deviation control. | Hybrid. |
| Seagen | OncADC Safety critical paths; CPMs own AESI cadence. | Hybrid. |
| Daiichi Sankyo | ADCOnc Biomarker logistics; global alignment. | Hybrid. |
| Astellas | OncUrology GU networks; cross-affiliate starts. | Hybrid. |
| BeiGene | Heme/Onc Multi-country oversight; TMF discipline. | Hybrid. |
| Exelixis | Onc TKI programs; timeline triage. | Hybrid. |
| Karyopharm | Heme MM/CLL complexity; risk boards. | Hybrid. |
| Mirati (BMS) | Onc Precision enrollment nuance. | Hybrid. |
| Genmab | Heme/Onc Antibody modalities; vendor control. | Hybrid. |
| Immunocore | TCROcular Specialty site alignment. | Hybrid. |
| Acrivon | Precision Onc Biomarker gating; CPM owns KRI. | Hybrid. |
| BioMarin | RareGenetic COE activation; registry literacy. | Hybrid. |
| Ultragenyx | RareMetabolic Pediatric nuance; caregiver timelines. | Hybrid. |
| Sarepta | Gene Tx Site start-up choreography; supply chain sync. | Hybrid. |
| Bluebird bio | Gene TxHeme Apheresis/infusion planning; risk gates. | Hybrid. |
| CRISPR Therapeutics | Gene Editing Emerging label risk; KRI dashboards. | Hybrid. |
| Editas Medicine | Gene EditingOcular Retina COEs; specialized vendors. | Hybrid. |
| Ionis | ASONeuro/Cardio Endpoint logistics; DMC readiness. | Hybrid. |
| Alnylam | RNAiRare Country submissions cadence. | Hybrid. |
| PTC Therapeutics | RareNeuro Pediatric timelines; partner oversight. | Hybrid. |
| Sana Biotechnology | Cell/Gene Early-phase orchestration; safety boards. | Hybrid. |
| Moderna | VaccinesResp Fast starts; global affiliate sync. | Hybrid. |
| BioNTech | IOVaccines Translational timelines; quality gates. | Hybrid. |
| Novavax | Vaccines Country activation grids; supply nuance. | Hybrid. |
| Apellis | ComplementOphth Retina/site sequencing; safety cadence. | Hybrid. |
| Santen | Ophthalmology Clinic flow; imaging vendors. | Hybrid. |
| Ferring | GIFertility Multi-stakeholder schedules. | Hybrid. |
| Galderma | Derm Practice-based sites; AE vigilance. | Hybrid. |
| Leo Pharma | Derm Real-world adherence programs. | Hybrid. |
| Regeneron | OphthImmunology Specialty COEs; tight KRIs. | Hybrid. |
| Horizon (Amgen) | ImmunologyRare Long-tail follow-through; PMO strength. | Hybrid. |
| Exact Sciences | Onc-Dx Screening/MRD study ops; lab sync. | Hybrid. |
| Guardant Health | Onc-Dx Liquid biopsy timelines; payer evidence. | Hybrid. |
| Natera | MRD Sample logistics; real-time monitoring. | Hybrid. |
| Foundation Medicine | Genomics Path-onc integration; report cadence. | Hybrid. |
| Invitae | Genetics Referral flows; site education ops. | Hybrid. |
| Velocity Clinical Research | Site Network Start-up speed; CPMs align sponsor asks. | Hybrid. |
| Parallel (former PPD SN) * | Site Ops KPI discipline; activation playbooks. | Hybrid. |
| PMG Research | Sites Enrollment orchestration; quality rhythm. | Hybrid. |
| Synexus (HCA ties) | Sites Large-scale recruitment; CPM interface. | Hybrid. |
| ClinEdge/OCASA | Site Services Patient services + study ops. | Remote/hybrid. |
| Mayo Clinic Research | Academic Complex governance; multi-PI projects. | Hybrid on-site. |
| Cleveland Clinic | Academic High SOP rigor; device + drug. | Hybrid. |
| Mass General Brigham | Academic Multi-department trials; PMO cadence. | Hybrid. |
| MD Anderson | Onc Protocol complexity; data safety cadence. | Hybrid. |
| UPMC | Academic Regional multi-site orchestration. | Hybrid. |
| PRA (legacy within ICON) | Global Process muscle; CPM escalations. | Hybrid. |
| CROMSOURCE | EMEA/US Start-up & monitoring sync. | Remote/hybrid. |
| Synteract (Syneos) | Small/Mid Agile CPM squads. | Hybrid. |
| ClinChoice | Global FSP/Full-service hybrids. | Remote. |
| Rho | Gov/NIHBiotech Public-private rhythm; compliance calm. | Hybrid. |
| NAMSA | Med Device Design controls; MDR literacy. | Hybrid. |
| Pivotal | EU/US Oncology & rare ops cadence. | Hybrid. |
| Medelis | Onc Niche network coordination. | Remote. |
| ERM / ClinicalRM | Global Health Complex logistics; safety cadence. | Hybrid. |
| BioAgile Therapeutics | Small Biotech Scrappy CPM leadership. | Remote. |
| Karuna (BMS) | CNS Psychiatric endpoints; AE nuance. | Hybrid. |
| ACADIA | Psych Geri-psych programs; caregiver dynamics. | Hybrid. |
| Cytokinetics | CardioMuscle HF timelines; DMC prep. | Hybrid. |
| argenx | Autoimmune Infusion sites; safety KRIs. | Hybrid. |
| Travere | Rare Renal CKD endpoints; registry integration. | Hybrid. |
| Akebia | Nephrology Anemia programs; payer studies. | Hybrid. |
| Sobi | HemeRare Specialty networks; AE vigilance. | Hybrid. |
| CSL Behring | ImmunologyHeme Global site orchestration. | Hybrid. |
| CSL Vifor | Renal CKD clinics; supply forecasting. | Hybrid. |
| Valneva | Vaccines Seasonal timelines; country nuance. | Hybrid. |
| Grifols | PlasmaImmunology Infusion center ops; escalation gates. | Hybrid. |
| Organon | Women’s Health OB/GYN networks; access studies. | Hybrid. |
| Urovant | Urology Community sites; startup speed. | Hybrid. |
| Revance | Aesthetics Practice research; device-adjacent nuance. | Hybrid. |
| Helsinn | Onc Supportive AESI discipline; caregiver outcomes. | Hybrid. |
| Apellis | Complement Systemic hematology; safety boards. | Hybrid. |
| Lundbeck | CNS Community psychiatry; adherence nuance. | Hybrid. |
| Otsuka | PsychNephro Cross-specialty program ops. | Hybrid. |
| Takeda | IBDRare Global start-ups; hub-and-spoke CPM. | Hybrid. |
| Aimmune | Allergy Pediatric endpoints; site training cadence. | Hybrid. |
| Cognizant Life Sciences | FSPData CPMs bridge FSP pods to sponsor PMO. | Remote/hybrid. |
| Accenture Life Sciences | PMOSystems Governance and tooling rollouts. | Hybrid. |
| Genpact | FSPRBQM KRI dashboards; continuous CAPA. | Remote. |
| Tata Elxsi / TCS Life Sciences | FSPData Global delivery; CPM orchestration. | Hybrid. |
| Wipro Life Sciences | FSP Tooling migrations; TMF control. | Remote. |
| Zai Lab (US) | Onc Cross-regional ops; affiliate sync. | Hybrid. |
| Arkuda Therapeutics | Neuro Early-phase discipline; vendor control. | Hybrid. |
| Seres Therapeutics | Microbiome Manufacturing/logistics timing. | Hybrid. |
| SanaRx (Example SMB) | Small Biotech CPMs wear many hats; cadence kings. | Remote. |
| BridgeBio | GeneticCardio Cross-asset governance. | Hybrid. |
| Biohaven | Neuro Multi-center ops; KPI rigor. | Hybrid. |
| Apellis (Systemic) | Complement Cross-specialty trials; safety nuance. | Hybrid. |
| CSL Seqirus | Vaccines Seasonal cadence; start-up velocity. | Hybrid. |
| Exact Sciences (GI) | GI Dx Site/lab orchestration; reports cadence. | Hybrid. |
| Foundation Medicine (Path) | Pathology Report literacy; cross-team sync. | Hybrid. |
30–60–90 CPM plan (paste straight into onboarding)
Days 1–30 — Stabilize scope and risk. Stand up a live RAID log grounded in risk-management; lock Change-Control rules; and switch to ALCOA+ templates via GCP documentation practices. Run a country-by-country start-up map anchored in global trial trends and Brexit nuance. Publish a budget baseline using oversight methods.
Days 31–60 — Accelerate delivery. Use project planning to drive weekly SLAs for site start-up, monitoring, data locks. Convert deviations to CAPA with owners/dates. Tighten communication using PI leadership principles and keep messaging crisp with test-taking strategies.
Which CPM capability will move your trial fastest in 2025?
KPIs that predict CPM success (and how to lift them)
Start-up cycle ≤ target by country. Build a critical path with project planning and run a risk register tied to CAPA discipline.
Monitoring hit-rate ≥ 95% on time. Use KRIs to trigger centralized review; keep site follow-ups GCP-clean per documentation mastery.
Budget variance ≤ ±5%. Re-forecast monthly; tie deltas to actions using budget oversight.
TMF inspection readiness: green. Audit proof with ALCOA+ templates; lock version control and access logs.
Enrollment vs. plan: green. Map country trial dynamics from global trend intel; propose targeted rescue plans with start-stop clarity.
FAQs
-
Yes—hybrid-first is common. The differentiator is your asynchronous discipline: ALCOA+ notes per GCP documentation, weekly project planning cadences, and a visible risk→CAPA loop per risk management.
-
Strong fits include CRA Leads, Trial Start-Up Leads, and Data PMs—if they present budget oversight with oversight KPIs and GCP-clean documentation per ALCOA+.
-
Use a one-page region memo referencing countries leading trials in 2025 and Brexit-era UK dynamics; propose explicit risk gates and rescue triggers.
-
A live RAID excerpt, a budget variance → action plan, and a TMF readiness checklist. Keep phrasing sharp using test-taking strategies and leadership tone grounded in PI team management.
-
Ranges vary by TA and geography. Calibrate expectations with 2025 salary data; anchor negotiations to enrollment wins, cycle-time cuts, and variance control documented with GCP-clean evidence.
